A tumor is an abnormal mass of tissue that forms when cells grow and divide more than they should, or fail to die when they normally would. Tumors can be benign, meaning they stay put and rarely threaten life, or malignant, meaning they invade surrounding tissue and can spread to distant organs. The biology behind how a clump of rogue cells emerges, sustains itself, evades the body’s defenses, and sometimes lies dormant for years before returning is far more layered than the simple image of “cells growing out of control” suggests.
How a Tumor Begins
Every tumor starts with genetic changes in a cell. Two broad categories of genes matter most. The first are oncogenes, which when mutated gain new functions that push a cell to grow and divide without the usual stop signals. The second are tumor-suppressor genes, which normally act as brakes on cell division and DNA copying. When these brakes are knocked out by mutations, cells lose a critical layer of quality control.1Trends in Molecular Medicine. Identifying and annotating driver mutations in cancer: computational methods and approaches A single mutation is rarely enough to produce a dangerous tumor. Research suggests that benign tumors typically carry two or three key mutations, while malignant tumors accumulate four or more, along with additional mutations that drive progression toward invasion and spread.2PubMed. The difference between benign and malignant tumours explained with the 4-mutation paradigm for carcinogenesis
But genetic mutations in the DNA sequence are only part of the picture. Cells can also be derailed by epigenetic changes, which alter how genes are read without changing the underlying code. These include chemical tags added to DNA or to the proteins that package it, as well as small RNA molecules that silence specific genes. These disruptions can happen early in a tumor’s life and are considered key players in cancer progression.3PubMed Central. Epigenetic modifications in cancer One reason this matters practically is that epigenetic changes, unlike permanent DNA mutations, are reversible. That has opened an entire class of drugs designed to reset gene-reading patterns in cancer cells.
Benign Versus Malignant
The word “tumor” does not automatically mean cancer. Benign tumors, such as lipomas in fatty tissue or fibroids in the uterus, tend to grow slowly, stay enclosed in a capsule, and closely resemble the normal tissue they came from. They can still cause problems if they press on nerves, blood vessels, or organs, but they do not invade neighboring tissue or travel to other parts of the body.
Malignant tumors are a different story. They grow faster, look less like normal tissue under a microscope, break through tissue boundaries, and can seed new growths in distant organs through metastasis. The shift from benign to malignant behavior tracks with additional mutations that unlock capabilities like invasion, immune evasion, and the ability to recruit a blood supply.4PubMed. The difference between benign and malignant tumours explained with the 4-mutation paradigm for carcinogenesis Not all benign tumors become malignant; most never will. But some, like certain colon polyps, have a well-documented path from benign to cancerous over years, which is why screening programs exist to catch and remove them early.
How Tumors Feed and Fuel Themselves
A tumor cannot grow beyond a tiny size without a blood supply. The process by which tumors recruit new blood vessels is called angiogenesis, and it is orchestrated by signaling molecules that tumor cells release. The biology gets complicated because tumor blood-vessel growth does not follow a single script. It varies by cancer type and body location, and multiple vessel-forming processes can happen simultaneously within the same tumor.5PubMed Central. Tumor angiogenesis: causes, consequences, challenges and opportunities Many of the signals involved are the same ones the body uses during normal development to build blood vessels, but in a tumor they run without the usual feedback controls and are heavily influenced by inflammation and low oxygen.6PubMed Central. Molecular mechanisms of tumor angiogenesis
Tumors also rewire their internal energy metabolism. Even when they have perfectly functional energy-producing machinery in their cells, many cancer cells preferentially gulp up glucose and ferment it into lactate rather than burning it efficiently. This shift, known as the Warburg effect, supports rapid growth and provides raw materials for building new cells.7PubMed Central. The Warburg Effect: How Does it Benefit Cancer Cells? The metabolic interplay goes further: surrounding non-cancerous cells can also shift to this mode of metabolism, producing lactate that feeds the cancer cells and buffering the acidic conditions that would otherwise slow tumor growth.8PubMed Central. Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication This metabolic cooperation between a tumor and its surroundings is one reason cancer is so hard to starve out.
The Neighborhood Around a Tumor
A tumor is not just a ball of cancer cells. It exists within a microenvironment made up of structural scaffolding, immune cells, blood vessels, and signaling molecules. The structural scaffolding, called the extracellular matrix, gets remodeled as a tumor grows. Changes in its composition, the enzymes that break it down, and its physical stiffness all influence how the tumor behaves. The remodeled matrix acts as a physical barrier that shields cancer cells from both the immune system and therapeutic drugs.9PubMed Central. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments
One underappreciated aspect of this physical environment is pressure. Solid tumors typically have elevated internal fluid pressure, which increases from the edges toward the center. This elevated pressure is both a marker of aggressive behavior and a direct obstacle to treatment, because it hinders the penetration of drugs into the tumor’s core.10PubMed. Interstitial fluid pressure as an emerging biomarker in solid tumors Researchers have shown that techniques like pulsed focused ultrasound can safely reduce this pressure and improve the delivery of drug-carrying particles deeper into tumor tissue.11PubMed Central. Pulsed focused ultrasound lowers interstitial fluid pressure and increases nanoparticle delivery and penetration in head and neck squamous cell carcinoma xenograft tumors
How Tumors Dodge the Immune System
Your immune system has powerful tools for recognizing and killing abnormal cells. Tumors survive in part because they learn to exploit the immune system’s own off-switches. The most studied of these is the PD-1/PD-L1 pathway. Normally, PD-1 on immune cells binds to PD-L1 on healthy cells as a signal to stand down, preventing autoimmune attacks. Cancer cells hijack this system by displaying PD-L1 on their surface, effectively telling approaching immune cells to back off. This dampens the activity of the T cells that would otherwise destroy the tumor while promoting regulatory immune cells that suppress immune responses further.12PubMed Central. Regulatory mechanisms of PD-1/PD-L1 in cancers The discovery of this mechanism is what made checkpoint-inhibitor immunotherapy possible, with drugs designed to block the PD-1/PD-L1 handshake and let immune cells do their job.
How Tumors Spread
Metastasis is the process responsible for most cancer deaths. For a cancer cell to spread, it has to detach from the primary tumor, invade surrounding tissue, enter the bloodstream or lymphatic system, survive the journey, exit at a distant site, and establish a new growth. One of the central programs that enables this is a developmental process that cells co-opt to become more mobile and resistant to death. During this shift, cancer cells take on properties that allow them to move individually through tissue, resist the normal self-destruct signals, and acquire features resembling stem cells.13PubMed. Epithelial Mesenchymal Transition in Tumor Metastasis
Recent research shows this transition is not all-or-nothing. In pancreatic, breast, and colorectal cancers, many tumor cells undergo only a partial version of this shift, losing some of their normal epithelial traits through protein recycling rather than shutting down the genes entirely. These partially shifted cells tend to migrate as clusters rather than individually, and the distinction matters because cluster-based migration and single-cell migration represent different modes of invasion with potentially different vulnerabilities.14PubMed Central. EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration
Why the Same Tumor Contains Different Cells
If you could sample different regions of a single tumor, you would often find genetically distinct subpopulations of cancer cells. This internal diversity, called intratumoral heterogeneity, is one of the biggest obstacles to effective treatment. It arises because tumor cells keep mutating as they divide, and selective pressures from the immune system and therapies shape which clones thrive.15Cell. Tumor Evolution
The clinical consequences are sobering. Whole-genome sequencing of medulloblastomas before and after therapy found that most drug targets identified before treatment appeared to be present throughout the tumor but turned out to be restricted to subgroups of cells, and some were absent entirely when the cancer came back. In gastric cancers, only tumors where the target gene was amplified broadly across the cell population responded to the matching drug; those with patchy amplification did not.16Cell. Tumor Evolution Tumors that harbor many different clones are often resistant to single-agent therapy and more likely to recur, which is why researchers are exploring multi-targeted approaches.17PubMed Central. Tumor heterogeneity, clonal evolution, and therapy resistance: an opportunity for multitargeting therapy
When Tumors Go Silent and Then Return
Some cancer cells can enter a dormant state after apparently successful treatment, sitting quietly in distant tissues for months, years, or even decades before waking up and producing a recurrence. This dormancy is not simply a matter of leftover cells growing slowly. Dormant cancer cells actively interact with their surroundings, and their entry into and exit from the dormant state is influenced by immune cells, the structural scaffolding of the tissue they have landed in, local stromal cells, and stressors like oxidative damage.18PubMed Central. Dormant cancer cells: programmed quiescence, senescence, or both? Understanding what triggers the “wake-up” signal is one of the open frontiers in cancer research, with implications for preventing late relapses in cancers like breast cancer, melanoma, and prostate cancer that are known for recurrences long after treatment.19PubMed Central. Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence
Early Detection Through Blood Tests
Tumors shed fragments of their DNA into the bloodstream, and this circulating tumor DNA can be picked up through a simple blood draw, sometimes called a liquid biopsy. Studies have found that screening for genetic mutations in circulating tumor DNA is both highly sensitive and specific, suggesting it could improve tumor diagnosis and even catch cancers at earlier stages than traditional imaging.20PubMed Central. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer The technology holds particular promise for cancers that currently lack good screening methods, such as ovarian, pancreatic, and gastric cancers. Researchers are also finding that combining circulating tumor DNA analysis with other biological markers and patient information can further improve early detection.21PubMed Central. Circulating tumor DNA as an early cancer detection tool
Environmental and Lifestyle Roots
One of the most striking findings in cancer research is how few cases are driven purely by inherited genetic defects. Estimates suggest that only about 5 to 10 percent of cancers trace to inherited mutations, while the remaining 90 to 95 percent have roots in environmental exposures and lifestyle factors, including smoking, diet, alcohol, sun exposure, infections, obesity, and physical inactivity. Chronic inflammation appears to be a common thread linking many of these risk factors to tumor development.22PubMed Central. Cancer is a preventable disease that requires major lifestyle changes Regional cancer patterns worldwide reinforce this, with dietary habits and environmental conditions correlating meaningfully with local cancer incidence rates.23PubMed Central. Global trends of cancer: The role of diet, lifestyle, and environmental factors
This does not mean lifestyle changes guarantee you will never develop a tumor, but it does mean the window for risk reduction is far larger than most people assume. The framing of cancer as primarily a “genetic disease” can be misleading when the vast majority of cases are driven by exposures and behaviors that accumulate over a lifetime.
Newer Therapeutic Strategies
Despite the complexity of tumor biology, the therapeutic landscape has expanded considerably. One important concept is oncogene addiction: even though most cancers carry many mutations, many tumors are disproportionately dependent on a single activated oncogene for their survival. Blocking that one gene can sometimes collapse the entire tumor, which is the principle behind targeted therapies like those used in certain lung cancers and leukemias.24PubMed Central. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Immunotherapy has been one of the most significant advances. Checkpoint inhibitors that block the PD-1/PD-L1 pathway have shown dramatic results in some patients, but solid tumors remain harder to treat than blood cancers because immune cells struggle to penetrate the tumor microenvironment. One approach to this problem combines engineered immune cells (CAR T cells) with checkpoint blockade. The idea is that CAR T cells can infiltrate tumors that are otherwise invisible to the immune system, while checkpoint blockade prevents the tumor from shutting those cells down. In preclinical studies, this combination outperformed either approach alone.25PubMed Central. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Another emerging strategy uses engineered viruses that selectively infect and kill cancer cells. These oncolytic viruses work through multiple channels: directly destroying tumor cells, releasing tumor proteins that alert the immune system, disrupting the tumor’s supportive microenvironment, interfering with its energy metabolism, and cutting off its blood supply.26PubMed Central. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy
Childhood Tumors Are a Different Disease
Pediatric cancers and adult cancers may share the word “cancer,” but genetically they look quite different. Adult tumors tend to carry substantially higher numbers of mutations, accumulated over decades of cell division and environmental exposure. Childhood tumors typically have far fewer mutations, and the types of genetic alterations driving them are often distinct from those seen in adults.27PubMed Central. Genomics of adult and pediatric solid tumors This has practical consequences: treatments designed around heavily mutated adult tumors do not always translate to pediatric cancers, and children’s cancers sometimes respond to entirely different therapeutic approaches. The lower mutational burden in childhood tumors also means that inherited genetic factors and developmental biology play a proportionally larger role in how these cancers arise.
Microbes Living Inside Tumors
One of the more surprising discoveries in recent cancer research is that tumors are not sterile. Bacteria, viruses, and fungi have been found living within tumor tissues themselves, forming what researchers now call the intratumoral microbiome. These microbial communities have a two-faced relationship with cancer: they can both promote and suppress tumor growth, depending on the species involved and the context. Some intratumoral microbes interact with immune cells in ways that push the immune environment toward a suppressive state, helping the tumor grow and evade detection.28PubMed Central. Intratumoral microbiome: implications for immune modulation and innovative therapeutic strategies in cancer This is still a young area of research, but it has already opened new questions about whether manipulating the tumor’s microbial residents could improve treatment outcomes.
Why Whales Do Not Get More Cancer Than Mice
If cancer is fundamentally about cells accumulating mutations, you might expect that animals with more cells, or longer lifespans, would get cancer at much higher rates. They do not. Animals with a thousand times more cells than humans do not show increased cancer risk, a puzzle known as Peto’s paradox.29PubMed Central. Peto’s Paradox: evolution’s prescription for cancer prevention The resolution appears to be that large-bodied and long-lived species have evolved extra copies of tumor-suppressor genes. Cross-species gene analysis has found remarkable examples: microbats carry over 60 copies of a gene involved in stopping cell division after DNA damage, while other mammals have just one. Elephants, famously, carry multiple copies of TP53, the gene most commonly mutated in human cancers, and redundant copies of this gene have been shown experimentally to reduce tumor formation.30PubMed Central. Solutions to Peto’s paradox revealed by mathematical modelling and cross-species cancer gene analysis Studying how evolution solved the cancer problem in other species is providing blueprints that could eventually inform new prevention strategies for humans.